Neogenomics stock hits 52-week high at 15.56 USD By Investing.com
NeoGenomics Inc. stock recently hit a 52-week high of $15.56, indicating strong investor confidence with a 100.79% total return according to InvestingPro data. The company has also been active with financial maneuvers, including pricing $275 million in convertible senior notes, and has received upgraded ratings and increased price targets from analysts like Needham and Leerink Partners due to strong Q1 results and positive outlook.
Neogenomics stock hits 52-week high at 15.56 USD By Investing.com
NeoGenomics Inc. stock has reached a 52-week high of $15.56, reflecting a 110.94% increase over the past year. Despite being considered overvalued by InvestingPro, the company recently announced a $275 million convertible senior notes offering and welcomed Carolyn Starrett to its board. Analysts at Needham and Leerink Partners have reiterated or upgraded their ratings, citing strong Q1 results and positive revenue guidance for 2026.
NEO - Neogenomics Inc Latest SEC Filings
This article provides the latest SEC filings information for Neogenomics Inc (NEO), along with a detailed overview of its financial data, stock performance metrics, and key ratios. It includes market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various performance indicators.
Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?
NeoGenomics (NEO) has appointed Carolyn Starrett, a former Flatiron Health CEO known for her expertise in AI and healthcare data, to its Board of Directors. This move, combined with its Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to differentiate its services and improve long-term growth. While this could lead to more predictable growth and narrower losses by leveraging AI and real-world data, investors should be aware of the inherent risks, including ongoing losses and revenue volatility from pharma and biotech demand.
Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?
NeoGenomics (NEO) recently appointed Carolyn Starrett, an experienced healthcare data and AI leader, to its Board of Directors. This move, coupled with the Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to build a differentiated software layer around its lab services. The article explores how Starrett's expertise could influence the company's long-term business direction and potential for predictable growth, despite immediate risks like pharma services volatility.
Enterprise value to EBIT forward of NeoGenomics, Inc. – NASDAQ:NEO
This article focuses on the enterprise value to EBIT forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data and analysis specific to this valuation ratio. The article is hosted on TradingView, a financial platform offering various market tools and data.
Enterprise value to EBITDA forward of NeoGenomics, Inc. – NASDAQ:NEO
This article provides financial information for NeoGenomics, Inc. under the NASDAQ ticker NEO, specifically focusing on its enterprise value to EBITDA forward. It indicates basic financial data for the company is available through TradingView.
NeoGenomics, Inc. Actuals & Estimates (NASDAQ:NEO)
This article provides an overview of NeoGenomics, Inc. (NASDAQ: NEO) stock, covering its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's recent financial results, including earnings, revenue, and net income, alongside its employee count and EBITDA. The content encourages investors to conduct thorough research using financial data and technical analysis available on TradingView.
Price to sales forward of NeoGenomics, Inc. – NASDAQ:NEO
This page provides financial data for NeoGenomics, Inc. (NASDAQ: NEO), specifically its price to sales forward metric. The content highlights the company's financials, news, and other relevant market information on TradingView. It appears to be a stub or a data-only content piece without a detailed article.
Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO
This article focuses on the enterprise value to revenue forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data for the company under the NASDAQ stock market. The content primarily consists of navigational elements and data sourcing information, with the core financial metric appearing
NEO Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for NeoGenomics, Inc. (NEO), based on analyst ratings and future predictions for 2027. It details the company's current stock performance, market capitalization, volatility, and addresses frequently asked questions regarding its financial reports, earnings, revenue, net income, dividends, and employee count. The article concludes with a strong buy rating recommendation based on current technical analysis.
Carolyn Starrett joins NeoGenomics board of directors team
NeoGenomics Inc. has appointed Carolyn Starrett to its board of directors. This announcement is part of a broader update on new hires and leadership appointments within various SWFL businesses. Other organizations like Collaboratory, Priority Marketing, and Capital Wealth Advisors also made recent staffing changes.
NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants
NeoGenomics director Carolyn S. Starrett was granted 14,125 Restricted Stock Units and stock options for 9,784 shares of common stock on June 23, 2026. The stock options have an exercise price of $11.20 per share and expire on June 1, 2036. These equity awards are compensation grants, not open-market purchases, and are held directly by Ms. Starrett.
NeoGenomics, Inc. Actuals & Estimates (FWB:NG9)
This article provides an overview of NeoGenomics, Inc. (FWB:NG9) financial data and analyst estimates, including income statement, balance sheet, and cash flow information. It details stock performance, analyst price targets, and key financial metrics like earnings per share, revenue, and EBITDA. The report also mentions the company's employee count and its next earnings release date.
NeoGenomics, Inc. Actuals & Estimates (DUS:NG9)
This article provides financial actuals and estimates for NeoGenomics, Inc. (NG9) on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst price targets. Key information includes a max price estimate of 21.28 EUR, upcoming earnings on August 5, 2026, and recent financial performance such as Q4 earnings per share of 0.01 EUR and revenue of 161.57 M EUR.
NeoGenomics (NEO) director Carolyn Starrett files initial Form 3
NeoGenomics (NEO) director Carolyn Starrett has filed an initial Form 3 with the SEC, indicating her new status as a reporting insider for the company. The filing shows no transactions or holdings at this time, serving as an initial disclosure of beneficial ownership. This transparency tool helps investors track insider stakes and potential future trading activities.
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
This article reviews the Q1 earnings of several testing and diagnostics services stocks, highlighting NeoGenomics (NEO), Guardant Health (GH), RadNet (RDNT), Labcorp (LH), and Quest Diagnostics (DGX). It notes that the industry as a whole reported strong Q1 results, with revenues beating estimates and share prices performing well. Guardant Health was identified as the top performer, while Labcorp had the weakest performance against analyst estimates.
NG9 Forecast — Price Target — Prediction for 2027
This article provides an overview of NeoGenomics, Inc. (NG9) stock, including analyst price targets, historical highs and lows, and key financial data. It highlights that 9 analysts predict a 1-year price target of 12.81 EUR, with a maximum estimate of 21.28 EUR and a minimum of 9.36 EUR. The company's next earnings report is set for August 5, 2026, and it does not pay dividends.
NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors
NeoGenomics, Inc. has announced the appointment of Carolyn Starrett to its Board of Directors. Starrett brings over 25 years of experience in data and technology companies, with significant expertise in AI and data insights within cancer care. Her prior roles include CEO of Flatiron Health and a board directorship at Foundation Medicine.
Does NeoGenomics' (NEO) 2032 Convertible Note Deal Reveal a New Oncology Diagnostics Playbook?
NeoGenomics recently completed a US$275 million convertible note offering due in 2032, following presentations at the 2026 ASCO meeting. This financing aims to improve balance sheet flexibility, refinance existing debt, and support initiatives like PanTracer, pushing out maturities but also introducing potential dilution concerns. Investors are now evaluating how this capital injection will support higher-value oncology diagnostics and affect the company's growth, funding model, and path to profitability.
NeoGenomics Appoints Carolyn Starrett to Board of Directors
NeoGenomics Inc. has appointed healthcare technology executive Carolyn Starrett to its Board of Directors to enhance its precision medicine and cancer diagnostics capabilities. Starrett brings over 25 years of experience in healthcare technology, data analytics, and AI, including a decade as CEO of Flatiron Health. Her expertise is expected to support NeoGenomics' long-term growth and innovation in oncology diagnostics.
NeoGenomics Taps AI Veteran for Board, Signaling Data-Driven Future
NeoGenomics has appointed Carolyn Starrett, a leader in healthcare technology and AI, to its Board of Directors, signaling a deepened investment in AI and real-world data for precision oncology. Starrett, former CEO of Flatiron Health, brings extensive experience in leveraging large-scale data to transform cancer care. This strategic move aims to accelerate NeoGenomics' AI-driven capabilities and strengthen its position in the rapidly growing AI in oncology market.
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics, Inc. has announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of experience in data and technology companies, with a focus on AI and data insights in cancer care. Her previous roles include CEO of Flatiron Health and a Board Director at Foundation Medicine, and she is expected to contribute significantly to NeoGenomics' expansion and patient impact.
NeoGenomics taps Flatiron ex-CEO Carolyn Starrett for its board
NeoGenomics, Inc. (NASDAQ: NEO) has appointed Carolyn Starrett to its Board of Directors. Starrett, the former CEO of Flatiron Health, brings over 25 years of experience in data and technology with a deep understanding of AI and data insights in cancer care. Her expertise is expected to help NeoGenomics expand its portfolio and enhance its impact on cancer patients through innovative diagnostic solutions.
Carolyn Starrett joins NeoGenomics (NEO) board, expanding oncology and AI expertise
NeoGenomics, Inc. (NASDAQ: NEO) has appointed Carolyn S. Starrett to its Board of Directors, increasing the board size from nine to ten members. Ms. Starrett brings over 25 years of experience in data, technology, and oncology, including executive roles at Flatiron Health, and will serve until the 2027 annual meeting. Her expertise in real-world data, AI, and analytics is expected to support NeoGenomics' oncology diagnostics and precision medicine strategy.
NeoGenomics appoints Carolyn Starrett to board of directors
NeoGenomics, Inc. has announced the appointment of Carolyn Starrett to its board of directors, leveraging her 25 years of experience in data and technology companies, including her previous role as CEO of Flatiron Health. Starrett's expertise in real-world data and analytics in cancer care is expected to support NeoGenomics' portfolio expansion efforts. The company, which provides oncology diagnostic solutions, has seen an 80% stock return over the past year and analysts anticipate it will achieve profitability this year.
NeoGenomics appoints Carolyn S. Starrett to its Board
NeoGenomics has appointed Carolyn S. Starrett to its Board of Directors, increasing the board size to ten members. Her appointment was effective June 23, 2026. Ms. Starrett will serve until the 2027 annual meeting and will receive standard independent director compensation.
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics, Inc. has announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of experience in data and technology companies, with a focus on AI and data insights in cancer care. Her prior roles include CEO of Flatiron Health and a Board Director at Foundation Medicine, and she is expected to provide valuable insights for NeoGenomics' expansion in oncology diagnostics.
Does NeoGenomics' (NEO) 2032 Convertible Note Deal Reveal a New Oncology Diagnostics Playbook?
NeoGenomics recently completed a US$275 million convertible note offering following oncology research presentations, combining capital raising with scientific visibility. This deal could reshape views on the company's balance sheet flexibility and long-term oncology diagnostics positioning. While the notes improve financial flexibility, they also introduce potential dilution, making growth execution and margin improvement critical for investors.
NeoGenomics, Inc. Announces $316 Million Offering of 0.75% Convertible Senior Notes Due 2032 and Indenture Agreement – Minichart
NeoGenomics, Inc. announced the pricing of a $316 million offering of 0.75% Convertible Senior Notes due 2032. Concurrently, the company entered into capped call transactions to mitigate potential share dilution and repurchased approximately $276 million of its existing 0.25% convertible senior notes due 2028. These actions aim to improve the company's capital structure and reduce debt, though investors should be aware of potential future share dilution.
Form 8K NeoGenomics Inc For: 22 June By Investing.com
This article reports that NeoGenomics Inc. filed a Form 8K on June 22. It briefly mentions the company and its stock performance, noting a +0.63% change for NEO. The content primarily consists of market data, news headlines, and various financial instrument performances.
NeoGenomics (NASDAQ: NEO) sells $316M converts, refinances 2028 notes
NeoGenomics, Inc. has successfully completed a private offering of $316.25 million in 0.75% Convertible Senior Notes due 2032. This strategic move includes the refinancing of approximately $276.0 million of its existing 0.25% convertible notes due 2028 and the implementation of capped call transactions to mitigate potential share dilution. The new notes have an initial conversion price of approximately $14.16 per share, representing a 35% premium over the share price on June 16, 2026.
NeoGenomics Prices $316.25M 0.75% Convertible Notes Due 2032; Adds Capped Calls, Repurchases Debt
NeoGenomics has completed a $316.25 million offering of 0.75% Convertible Senior Notes due 2032 to enhance liquidity and refinance its 2028 notes. The company also implemented capped call transactions to reduce dilution, repurchased approximately $276.0 million of its 2028 notes, and will buy back up to $25.0 million in common stock from note purchasers. These strategic financial moves aim to optimize NeoGenomics' capital structure and manage potential equity overhang.
NeoGenomics Stock Rises as 2032 Convertible Notes Price at 35% Premium
NeoGenomics Inc. (NASDAQ: NEO) stock rose over 7% after announcing positive clinical diagnostics news and a $275 million offering of 0.75% convertible senior notes due 2032. These notes, priced at a 35% premium to the prior close, will refinance existing debt and fund capped call transactions to mitigate dilution. The company's upcoming presentation of eight oncology-focused research abstracts at the 2026 ASCO meeting also contributes to investor optimism.
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) shares rose 7.2% to $11.13 in the last trading session, marking a 16.6% gain over the past four weeks and 39.8% over three months. The company is expected to report quarterly earnings of $0.03 per share with revenues projected at $197.25 million, an 8.8% increase year-over-year. Despite the recent surge, the Zacks Rank #3 (Hold) stock's future upside may depend on positive earnings estimate revisions, which have remained unchanged over the last 30 days.
Neogenomics Inc (NEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Neogenomics Inc (NEO), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, NEO has a price momentum score of 9.08 and is trading between a resistance level of 12.44 and a support level of 9.21. The analysis indicates a "Buy" signal based on moving averages and a mixed signal from other indicators, with 2 buy, 4 neutral, and 1 sell.
Neogenomics Inc (NEO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Neogenomics Inc (NEO) has an earnings forecast score of 7.83, ranking 37th in its industry, with an average price target of $13.00. Based on 12 analysts, the stock is rated as a "Buy" with a projected upside of +43.52%. Analysts expect the company's revenue to be $197.00M for the next quarter and EPS to be $0.03, up from -$0.08 in the previous quarter.
NeoGenomics prices $275M convertible notes offering at 0.75% By Investing.com
NeoGenomics Inc. has priced a private offering of $275 million in convertible senior notes due 2032, with an annual interest rate of 0.75%. The company plans to use the net proceeds to repurchase existing convertible notes and some common stock, aiming to manage its debt and capital structure. This move follows strong recent financial performance, with analysts maintaining positive outlooks and predicting profitability for the current year.
NeoGenomics (NASDAQ: NEO) director sells 5,307 shares in Form 4
NeoGenomics director Lynn A. Tetrault sold 5,307 shares of common stock at $11.10 per share on June 15, 2026, as reported in a Form 4 filing. After this transaction, she directly holds 86,115 common shares and indirectly holds 7,000 shares through an IRA. She also possesses restricted stock units and various stock options with exercise prices between $8.10 and $41.76.
NeoGenomics prices $275M convertible notes offering at 0.75%
NeoGenomics Inc. has priced a private offering of $275 million in convertible senior notes due 2032, carrying a 0.75% annual interest rate. The company plans to use the net proceeds, estimated at $266.15 million, to fund capped call transactions and repurchase an aggregate principal amount of its existing convertible senior notes due 2028. This move aligns with recent strong financial performance and positive analyst outlooks, including a "Buy" rating from Needham and an upgrade to "Outperform" from Leerink Partners.
NeoGenomics prices $275M convertible notes due 2032, plans repurchases of 2028 notes and shares
NeoGenomics has priced $275 million in convertible senior notes due 2032, with an option for initial purchasers to buy an additional $41.25 million. The company plans to use the net proceeds to repurchase a portion of its outstanding 2.50% convertible senior notes due 2028 and may also repurchase shares of its common stock.
NeoGenomics (NASDAQ: NEO) refinances converts, plans $25M buyback
NeoGenomics is privately offering $275 million in 0.75% convertible senior notes due 2032 to refinance existing debt and manage potential equity dilution. The company plans to use a significant portion of the proceeds to repurchase $276 million of its 0.25% convertible notes due 2028 and may also repurchase up to $25 million of its common stock. Capped call transactions will help mitigate dilution risk up to a 100% premium on the current stock price.
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
NeoGenomics has priced its private offering of $275 million in 0.75% convertible senior notes due 2032, with an option for initial purchasers to buy an additional $41.25 million. The offering is expected to close on June 22, 2026. The company plans to use the net proceeds to repurchase existing 2028 convertible notes, buy back common stock, and for general corporate purposes, while also entering into capped call transactions to reduce potential dilution.
NeoGenomics prices $275M convertible notes offering at 0.75%
NeoGenomics Inc. has priced a private offering of $275 million in convertible senior notes due 2032, carrying a 0.75% annual interest rate. The company plans to use the net proceeds, estimated at $266.15 million, to repurchase existing convertible notes and common stock. This move comes as NeoGenomics shows strong financial health with liquid assets exceeding short-term obligations and analysts predicting profitability for the current year.
(NEO) Price Dynamics and Execution-Aware Positioning
This article analyzes Neogenomics Inc. (NEO) stock dynamics, highlighting weak near-term sentiment that could shift. It presents an exceptional 81.0:1 risk-reward short setup and outlines three AI-generated trading strategies tailored to different risk profiles. The analysis also includes multi-timeframe signal data for near, mid, and long-term outlooks.
NeoGenomics launches $275M convertible notes offering
NeoGenomics Inc. (NASDAQ:NEO) has announced a private offering of $275 million in convertible senior notes due 2032 to refinance existing debt and manage potential share dilution. The oncology diagnostics company, with a $1.45 billion market cap, will use proceeds for capped call transactions, repurchasing a portion of existing notes, and potentially buying back up to $25 million of its common stock. Analysts predict the company will be profitable this year, with recent strong Q1 2026 earnings and positive analyst upgrades supporting a positive outlook.
NeoGenomics launches $275M convertible notes offering due 2032
NeoGenomics (NASDAQ:NEO) announced a private offering of $275 million in convertible senior notes due 2032 to qualified institutional buyers. The company also expects to grant the initial purchasers an option to buy up to an additional $41.25 million in notes. NeoGenomics plans to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.
NeoGenomics launches $275M convertible notes offering By Investing.com
NeoGenomics Inc. (NASDAQ:NEO) has announced a private offering of $275 million in convertible senior notes due 2032 to refinance existing debt. The company plans to use the proceeds for capped call transactions, repurchasing existing 2028 notes, and buying back up to $25 million of common stock, with remaining funds for general corporate purposes. Analysts predict profitability for the company this year, with EPS of $0.18 for fiscal 2026.
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. announced a private offering of $275 million in convertible senior notes due 2032 to qualified institutional buyers. The company also plans to grant initial purchasers an option for an additional $41.25 million. Proceeds will be used for capped call transactions, repurchasing existing 0.25% convertible senior notes due 2028, and potentially repurchasing up to $25 million of its common stock, with any remainder for general corporate purposes.
NeoGenomics launches $275M convertible notes offering due 2032 with $41.25M overallotment option
NeoGenomics has announced a proposed private offering of $275 million in convertible senior notes maturing in 2032, with an additional option for initial purchasers to buy up to $41.25 million more. The company plans to use the proceeds to partially repay existing convertible notes, repurchase shares, and for general corporate purposes, while also expecting to enter into capped call transactions to reduce share dilution. This offering is a private Rule 144A sale, with notes accruing semi-annual interest and being convertible or redeemable under specified conditions.
